Association Between Dose Reduction of Cyclin-dependent Kinase 4/6 Inhibitors and Survival in Advanced Breast Cancer: A Systematic Review and Meta-analysis
{{output}}
Aims: The integration of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors into the treatment regimen for advanced breast cancer (BC), specifically oestrogen receptor-positive (ER+) subtypes, marks a significant stride in oncologic... ...
